San Jose, Calif. – September 5, 2014 - MIBA Medical Inc., a medical aesthetics company, today announced their team traveled to FDA head quarter to have a sit down meeting for the pre-submission of their small volume soft tissue filler Restor. The face-to face meeting was to establish communication with the FDA and obtain clarifications and directives from the FDA for our pre-clinical and IDE submissions.
"I am extremely pleased that MIBA Medical Inc. has met with the FDA and has their guidance for the regulatory process." said Dr. Phi Nguyen, MIBA's Founder & CEO. ”This will allows us to tailor and streamline our regulatory process for our product Restor. It also gives us a clearer timeline and budget requirements and provides us with a good base for entering the regulatory approval phase from the FDA"
About MIBA Medical Inc.
MIBA Medical Inc. is a medical aesthetics company focused on developing and commercializing products that are used by physicians to enhance a patient's appearance. For more information, please visit http://www.mibamedical.com.